02:56 , Jun 4, 2013 |  BC Extra  |  Clinical News

Sanofi drops two Phase III compounds

Sanofi (Euronext:SAN; NYSE:SNY) said on Monday it discontinued development of two Phase III compounds: iniparib ( BSI-201 ), which was in development to treat non-small cell lung cancer (NSCLC) and ovarian cancer; and otamixaban (...
07:00 , Apr 29, 2013 |  BioCentury  |  Strategy

Zerhouni's progress report

When Elias Zerhouni joined Sanofi as the head of R&D in January 2011, the former NIH director decided the pharma's pipeline needed to be pruned and refocused around disease pathways. Two years into the job,...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Clinical News

Iniparib: Phase II data

Sanofi reported in its 2Q12 earnings that an open-label, European Phase II trial in 141 patients with stage II/IIIa TNBC showed that iniparib plus paclitaxel as neoadjuvant therapy "did not show any advantage in efficacy"...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

Iniparib: Additional Phase II data

Additional data from a single-arm, open-label, U.S. Phase II trial in 32 evaluable patients showed that IV BSI-201 plus gemcitabine and carboplatin produced an ORR of 25%. The most common adverse events were neutropenia, thrombocytopenia,...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

Iniparib: Additional Phase II data

Additional data from a single-arm, open-label, U.S. Phase II trial in 40 evaluable patients showed that IV BSI-201 plus gemcitabine and carboplatin produced an ORR of 65%. The most common adverse events were neutropenia, thrombocytopenia,...
07:00 , May 23, 2011 |  BC Week In Review  |  Clinical News

Iniparib: Additional Phase III data

Additional data from an open-label, U.S. Phase III trial in 519 women with metastatic triple-negative breast cancer showed that IV BSI-201 plus gemcitabine and carboplatin led to median OS and PFS, the co-primary endpoints, of...
07:00 , May 23, 2011 |  BC Week In Review  |  Clinical News

Iniparib: Preliminary Phase II data

Preliminary data from 19 evaluable patients in a single-arm, open-label, U.S. Phase II trial showed that IV BSI-201 plus gemcitabine and carboplatin produced an ORR of 31.6%, with a median PFS of 5.9 months. The...
07:00 , May 23, 2011 |  BC Week In Review  |  Clinical News

Iniparib: Preliminary Phase II data

Preliminary data from 17 evaluable patients in a single-arm, open-label, U.S. Phase II trial showed that IV BSI-201 plus gemcitabine and carboplatin produced an ORR of 70.6%. The trial plans to enroll 41 patients with...
08:00 , Jan 31, 2011 |  BC Week In Review  |  Clinical News

Iniparib: Phase III data

An open-label, U.S. Phase III trial in 519 women with metastatic triple-negative breast cancer showed that BSI-201 plus Gemzar gemcitabine and carboplatin missed the co-primary endpoints of significantly improving OS and PFS vs. Gemzar and...
01:56 , Jan 28, 2011 |  BC Extra  |  Clinical News

sanofi's iniparib misses breast cancer endpoints

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) said iniparib ( BSI-201 ) plus Gemzar gemcitabine and carboplatin missed the co-primary endpoints of significantly improving overall survival (OS) and progression-free survival (PFS) vs. Gemzar and carboplatin alone in an...